Plexium is the premier, next-generation targeted protein degradation company, seeking to discover a wide range of monovalent target protein degraders that address the limitations of PROTACs and cereblon.
The company’s platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases.
Company Details
- Employees
- 62
- Founded
- -
- Address
- 9330 Scranton Road,
- me****@****ium.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- plexium.com
- Keywords
- Manager jobs.
- HQ
- San Diego, California
Plexium Questions
Plexium's website is plexium.com
Plexium's LinkedIn profile is https://www.linkedin.com/company/plexium
Plexium has
62 employees.
View email and phone details for 62
employees at Plexium.
Plexium's industry is
Biotechnology Research
Plexium's top competitors are
Poseida Therapeutics, Inc.,
Zafrens,
Biotheryx, Inc.,
Neomorph, Inc.,
Iambic Therapeutics,
Crinetics Pharmaceuticals,
Neurocrine Biosciences,
1859,
Vividion Therapeutics, Inc.,
Omniome.
Plexium's support email address is media@plexium.com
Plexium's categories are Biotechnology Research
Plexium's founding year is 2018
